SCHEMBL5213167

SCHEMBL5213167

CN(C[C@H](O)c1cccc(O)c1)c1cnc(-c2ccccc2)c(-c2ccccc2)n1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CKS1B P61024 2/20 0.49
SKP1 P63208 2/20 0.49
SKP2 Q13309 2/20 0.49
MKNK1 Q9BUB5 5/20 0.48
SLC16A3 O15427 1/20 0.40
LMNA P02545 3/20 0.40
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
HIF1A Q16665 3/20 0.39
DRD1 P21728 2/20 0.39
ADRB2 P07550 1/20 0.39
ADRB1 P08588 1/20 0.39
HTR1A P08908 1/20 0.39
ADRA2A P08913 1/20 0.39
ADRB3 P13945 1/20 0.39
TSHR P16473 1/20 0.39
ADRA2B P18089 1/20 0.39
ADRA2C P18825 1/20 0.39
NFKB1 P19838 1/20 0.39
HTR7 P34969 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5213174 1.00 CKS1B (0.49) CKS1BSKP1SKP2MKNK1SLC16A3
SCHEMBL5215456 0.82 NR1I2 (0.47) CKS1BSKP1SKP2LMNAMEN1
SCHEMBL5584648 0.82 NR1I2 (0.47) CKS1BSKP1SKP2LMNAMEN1
SCHEMBL5215285 0.80 FAAH (0.46) CKS1BSKP1SKP2MEN1KMT2A
SCHEMBL5215295 0.80 FAAH (0.46) CKS1BSKP1SKP2MEN1KMT2A
SCHEMBL5214939 0.79 CKS1B (0.54) CKS1BSKP1SKP2KMT2ADRD1
SCHEMBL5219541 0.77 CKS1B (0.51) CKS1BSKP1SKP2DRD1DRD3
SCHEMBL1386196 0.72 PDK1 (0.43) MKNK1SLC16A3LMNAMEN1KMT2A
SCHEMBL6491739 0.70 HIF1A (0.56) MKNK1SLC16A3LMNAMEN1KMT2A
SCHEMBL3946482 0.70 ALOX5 (0.39) MKNK1SLC16A3LMNAMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7205302-B2 Anticoagulants; antilipemic agents; cardiovascular disorders NIPPON SHINYAKU CO., LTD. (JP) 2007-04-17 US disclosed
EP-1400518-B1 HETEROCYCLIC COMPOUND DERIVATIVES AND MEDICINES NIPPON SHINYAKU CO LTD (JP) 2007-01-17 EP disclosed
US-20040102436-A1 Heterocyclic compound derivatives and medicines NIPPON SHINYAKU CO., LTD. (JP) 2004-05-27 US disclosed
EP-1400518-A1 HETEROCYCLIC COMPOUND DERIVATIVES AND MEDICINES Nippon Shinyaku Co., Ltd. (JP) 2004-03-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040102436-A1 Heterocyclic compound derivatives and medicines CNR2, CNR1, GPR55 CKS1B 858/4885SKP1 2426/4885SKP2 3622/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.